Aldeyra Therapeutics, Inc

Add to watchlist
€10.6
Last updated:06/09/2021
137: F
Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye d… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-22.340589M
-38.893245M
-74.09%
-60.826831M
-56.39%
-37.553729M
+38.26%
Cashflow
Sum up money going in and out company
-19.222862M
-29.857131M
-55.32%
-44.984226M
-50.66%
-37.493455M
+16.65%
Total liabilities
All combined debts and obligations
4.573939M
8.473176M
+85.25%
27.435964M
+223.80%
23.843945M
-13.09%
Company profile
CEO
Dr. Todd C. Brady M.D., Ph.D.
Market capitalization
Small (0.63B)